期刊文献+
任意字段
题名或关键词
题名
关键词
摘要
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息
共找到189篇文章
< 1 2 … 10 >
每页显示 20 50 100
已选0条
引用分析
参考文献
引证文献
 统计分析
检索结果
已选文献
显示方式：
The role of radiomics in predicting the response to neoadjuvant chemotherapy for breast cancer 认领 引用
1
作者 Yilin Chen Ye Qin +5 位作者 Man Yang Wei Li Minyi Cheng Yuhong Huang Teng Zhu Kun Wang 《Cancer Biology & Medicine》 SCIE CAS CSCD 2026年第3期343-362,共20页
Breast cancer exhibits profound biological and spatial heterogeneity,which contributes to variable responses to neoadjuvant chemotherapy(NAC)and challenges precision treatment planning.Radiomics,an emerging discipline... Breast cancer exhibits profound biological and spatial heterogeneity,which contributes to variable responses to neoadjuvant chemotherapy(NAC)and challenges precision treatment planning.Radiomics,an emerging discipline that converts standard medical images into high-dimensional quantitative data,offers a non-invasive and reproducible means to capture tumor phenotype,heterogeneity,and treatment-induced changes.This review provides a comprehensive overview of recent advances in radiomics for breast cancer NAC,emphasizing the roles in predicting a pathologic complete response(pCR),monitoring early therapeutic efficacy,and quantifying intratumoral heterogeneity.Among imaging modalities,magnetic resonance imaging(MRI)-based radiomics,particularly utilizing dynamic contrast-enhanced and diffusion-weighted sequences,demonstrates robust predictive performance for the pCR,with multi-center studies reporting area under the curve(AUC)values>0.80.Longitudinal and delta-radiomics approaches further enhance early response evaluation by tracking temporal alterations in imaging features that precede measurable morphologic regression.Radiomic assessment of tumor heterogeneity,especially in triple-negative breast cancer(TNBC),reveals strong associations with immune infiltration,metabolic reprogramming,and therapeutic resistance,providing mechanistic insight into radiomic biomarkers.Integrative multi-omics frameworks,combining radiomics with genomics,transcriptomics and pathomics,are increasingly elucidating the biological underpinnings of imaging phenotypes,improving both model interpretability and clinical relevance.Despite these advances,widespread clinical adoption of radiomics is limited by methodologic variability,lack of standardization,and insufficient external validation.Future efforts should focus on harmonized imaging protocols,explainable artificial intelligence,and prospective multi-center trials to translate radiomics into a clinically actionable tool.Collectively,radiomics represents a transformative approach for individualized response prediction and dynamic treatment optimization in precision breast cancer management(Figure 1). 展开更多
关键词 Breast cancer radiomics neoadjuvant chemotherapy deep learning pathologic complete response
暂未订购 下载PDF
Primary Debulking Surgery Versus Neoadjuvant Chemotherapy in Advanced Ovarian Cancer:A Meta-Analysis of All Randomized Clinical Trials with Subgroup Analysis by Patient Profile 认领 引用
2
作者 Carlo Ronsini Giuseppe Cucinella +6 位作者 Maria Cristina Solazzo Mariano Catello Di Donna Cono Scaffa Stefano Cianci Manuela Ludovisi Sandro Pignata Vito Chiantera 《Oncology Research》 SCIE 2026年第5期43-56,共14页
Background:The optimal sequencing of surgery and chemotherapy in advanced epithelial ovarian cancer remains debated.While primary debulking surgery(PDS)has been considered the standard approach,recent randomized trial... Background:The optimal sequencing of surgery and chemotherapy in advanced epithelial ovarian cancer remains debated.While primary debulking surgery(PDS)has been considered the standard approach,recent randomized trials have questioned its survival advantage over neoadjuvant chemotherapy(NACT)followed by interval debulking surgery(IDS).The study aimed to systematically evaluate phase Ⅲ randomized controlled trials comparing PDS and NACT.Methods:Following PRISMA guidelines(PROSPERO ID 1169057),PubMed and Scopus were systematically searched in October 2025 for phase Ⅲ randomized clinical trials evaluating cytoreductive strategies in ovarian carcinoma.Only full-text English studies reporting overall survival(OS)or disease-free survival(DFS)were included.Risk ratios(RR)with 95%confidence intervals(CI)were calculated.Results:Five phase Ⅲ trials(EORTC 55971,CHORUS,JCOG0602,SCORPION,TRUST)comprising 2296 patients met the inclusion criteria.PDS(n=1139)and NACT(n=1157)showed comparable OS(RR 0.99,95%CI 0.94-1.03,p=0.55,I2=0%)and DFS(PDS RR 0.98,95%CI 0.95-1.02,p=0.27,I2=0%).Subgroup analyses confirmed the absence of significant differences for patients with CC0(RR 0.96,95%CI 0.87-1.05,p=0.35,I2=0%),FIGO stage Ⅲ disease(RR 0.97,95%CI 0.92-1.03,p=0.34,I2=0%),or age under 70 years(RR 1.03,95%CI 0.97-1.09,p=0.38,I2=0%).Conclusions:PDS and NACT provide no significant survival outcomes in advanced ovarian cancer.No clear survival benefit for PDS was observed.Refinement of patient selection,integration of predictive biomarkers,and re-evaluation of PDS in the context of HIPEC and Poly-ADP-Ribose Polymerase(PARP)inhibitor use are warranted to guide individualized treatment strategies. 展开更多
关键词 Advanced ovarian cancer primary cyoreductive surgery neoadjuvant chemotherapy cytoreductive surgery randomized controlled trials
暂未订购 下载PDF
Clinical value of geriatric nutritional risk index and pan-immune inflammation value in locally advanced gastric cancer receiving neoadjuvant chemotherapy 认领 引用
3
作者 Wen-Tao Zhong Shi-Kang Ding +3 位作者 Ru-Yin Li Cheng-Yu Liu Hong-Yun Huang Jian-Chun Yu 《World Journal of Gastrointestinal Oncology》 SCIE 2026年第2期163-179,共17页
BACKGROUND Metabolism and nutrition status play an important role in the development of cancer.However,whether inflammation and malnutrition related indicators can predict the efficacy of neoadjuvant chemotherapy(NACT... BACKGROUND Metabolism and nutrition status play an important role in the development of cancer.However,whether inflammation and malnutrition related indicators can predict the efficacy of neoadjuvant chemotherapy(NACT)and the prognosis of gastric cancer has not been addressed.AIM To evaluate the predictive value of malnutrition as determined by the geriatric nutritional risk index(GNRI)and inflammation represented by the pan-immuneinflammation value(PIV)for the response to NACT patients’prognosis in locally advanced gastric cancer(LAGC).METHODS We retrospectively analyzed 147 LAGC patients who underwent radical resection after NACT.The PIV,and GNRI were compared according to whether receiving nutritional intervention during NACT.The prognostic values of GNRI and PIV were assessed using time-dependent receiver operating characteristic curve analysis,log-rank tests,and Cox regression analysis.RESULTS Nutritional intervention could improve nutrition status and reduce inflammation during NACT in LAGC patients.Multivariate analysis showed that GNRI(hazard ratio=0.956,95%confidence interval:0.923-0.991,P=0.013),PIV(hazard ratio=1.002,95%confidence interval:1-1.005,P=0.041)were independent predictors for OS.Significant differences of overall survival and disease-free survival according to GNRI(P<0.001)and PIV(P<0.001)were observed between the low and high groups.The GNRI-PIV score constructed with GNRI and PIV had a higher area under the curve and was significantly associated with pathological tumor regression response.CONCLUSION GNRI and PIV are useful predictive biomarkers in patients with LAGC receiving NACT,and nutritional supplement can improve patients’status.The GNRI-PIV score may contribute to a more personalized and holistic approach for LAGC patients underwent NACT. 展开更多
关键词 Prognosis Neoadjuvant chemotherapy Locally advanced gastric cancer Pan-immune-inflammation value Geriatric nutritional risk index
暂未订购 下载PDF
Impact of anxiety and depression on quality of life in gastric cancer patients receiving SOX neoadjuvant chemotherapy 认领 引用
4
作者 Bo-Yang Cui Zhen Zhang 《World Journal of Gastrointestinal Oncology》 SCIE 2026年第7期190-199,共10页
BACKGROUND Gastric cancer(GC)is a leading cause of cancer mortality globally.The SOX neoadjuvant chemotherapy regimen is standard for early-to-mid-stage disease,but chemotherapy-related stress often induces psychologi... BACKGROUND Gastric cancer(GC)is a leading cause of cancer mortality globally.The SOX neoadjuvant chemotherapy regimen is standard for early-to-mid-stage disease,but chemotherapy-related stress often induces psychological distress.AIM To investigate the prevalence,risk factors of anxiety and depression in stage II-III GC patients receiving SOX neoadjuvant chemotherapy,and clarify their independent impacts on quality of life(QoL).METHODS A retrospective analysis was conducted on 153 patients with stage II-III GC receiving SOX regimen NACT at The Second Affiliated Hospital of Kunming Medical University Hospital.Anxiety and depression were assessed using the Zung Self-Rating Anxiety(SAS)and Zung Self-Rating Depression Scale(SDS)scales.QoL was evaluated with the QoL Questionnaire Core 30 questionnaire.Demographic,clinical data,and adverse reactions were collected.Multivariate logistic regression identified risk factors for anxiety/depression.Multiple linear regression analyzed the independent impact of psychological distress on global QoL.RESULTS The prevalence of anxiety(SAS≥50)and depression(SDS≥53)was 37.91%(58/153)and 39.87%(61/153),respectively;47.71%(73/153)had either symptom(anxiety-depression group).Independent risk factors for anxiety/depression included female gender[odds ratio(OR)=2.13,95%confidence interval(CI):1.03-4.40],unmarried/divorced/widowed status(OR=3.17,95%CI:1.28-7.85),primary school education or below(OR=3.50,95%CI:1.33-9.21),and clinical stage III(OR=2.69,95%CI:1.32-5.46).The anxiety-depression group had higher Grade III–IV gastrointestinal reactions(20.55%vs 8.75%,P=0.021).SAS/SDS scores negatively correlated with emotional(r=-0.552/-0.599),social(r=-0.403/-0.471),physical functioning(r=-0.369/-0.404),and global QoL(r=-0.539/-0.574,all P<0.001).After adjusting confounders,anxiety(β=-0.12,P=0.013)and depression(β=-0.14,P<0.001)independently predicted lower global QoL.CONCLUSION Anxiety and depression are common in early-to-mid-stage GC patients receiving SOX neoadjuvant chemotherapy,associated with specific demographic/clinical factors,severe gastrointestinal reactions,and poor QoL,highlighting the need for routine psychological screening and intervention. 展开更多
关键词 Anxiety Depression Gastric cancer Neoadjuvant chemotherapy Quality of life
暂未订购 下载PDF
Dynamic Changes of Peripheral Blood T Cell Subsets in Predicting the Efficacy of Neoadjuvant Chemotherapy for Lung Adenocarcinoma 认领 引用
5
作者 LIAO Lulu 《外文科技期刊数据库（文摘版）医药卫生》 2026年第5期052-058,共7页
Background: Platinum-based neoadjuvant chemotherapy (NAC) is standard perioperative therapy for resectable stage Ⅱ-ⅢA lung adenocarcinoma (LUAD), while heterogeneous pathological responses restrict clinical decision... Background: Platinum-based neoadjuvant chemotherapy (NAC) is standard perioperative therapy for resectable stage Ⅱ-ⅢA lung adenocarcinoma (LUAD), while heterogeneous pathological responses restrict clinical decision-making. Peripheral T cell subsets mediate systemic anti-tumor immunity, and chemotherapy-induced immune dynamics correlate with tumor immune microenvironment status and tumor regression. This study explored dynamic changes of peripheral CD3T, CD4T, CD8T, regulatory T cells (Tregs), PD-1 effector T cells and CD4/CD8 ratio during NAC, and identified immune biomarkers for predicting major pathological response (MPR) in LUAD.Methods: A total of 86 resectable stage Ⅱ-ⅢA LUAD patients receiving platinum-doublet NAC were enrolled prospectively from 2023 to 2025. All patients received 2-cycle NAC followed by radical lobectomy. Peripheral blood was collected at three time points: baseline T0, post-first-cycle chemotherapy T1, pre-operation T2. Flow cytometry detected T cell subset levels. Patients were divided into MPR and non-MPR groups according to postoperative pathology. Statistical analyses including t-test, chi-square test, repeated-measures ANOVA.Results: Among 86 patients, 39 cases (45.35%) achieved MPR and 47 cases (54.65%) did not. No baseline differences in clinical features and T cell subsets existed between two groups (all P>0.05). Early dynamic variation rate CD8 and Tregs were independent predictive factors for NAC efficacy (OR=4.216, 95%CI:2.135-8.327; OR=0.385, 95%CI:0.192-0.773, P<0.05).The combined CD8+Tregs index showed optimal predictive value with AUC=0.872, sensitivity 84.62% and specificity 82.98%.Conclusion: Early increased circulating CD8 effector T cells and decreased peripheral Tregs are non-invasive biomarkers for favorable NAC response in LUAD. Dynamic peripheral T subset monitoring can guide early efficacy assessment and individualized treatment for LUAD patients. 展开更多
关键词 Lung adenocarcinoma Neoadjuvant chemotherapy T lymphocyte subsets Dynamic change Major pathological response Predictive biomarker Flow cytometry
暂未订购 下载PDF
Effects of aerobic or resistance exercise during neoadjuvant chemotherapy on tumor response and therapy completion in women with breast cancer:The randomized controlled BENEFIT trial 认领 引用 被引量：2
6
作者 Martina E.Schmidt Siri Goldschmidt +6 位作者 Charlotte Kreutz Jana Müller Andreas Schneeweiss Anne M.May Friederike Rosenberger Joachim Wiskemann Karen Steindorf 《Journal of Sport and Health Science》 SCIE CSCD 2025年第6期67-75,167,共9页
Background The potential of exercise as a concurrent therapy for actively treated primary tumors has been suggested by emerging preclinical and observational studies.However,clinical trials regarding this question are... Background The potential of exercise as a concurrent therapy for actively treated primary tumors has been suggested by emerging preclinical and observational studies.However,clinical trials regarding this question are scarce.Therefore,we conducted a randomized controlled trial investigating the effects of aerobic or resistance exercise concomitant to neoadjuvant chemotherapy(NACT)on tumor size.Methods In the BENEFIT study(German title:Bewegung bei neoadjuvanter chemotherapie zur verbesserung der fitness),patients with breast cancer scheduled for NACT were randomly assigned to supervised resistance training(RT,n=60)or aerobic training(AT,n=60)twice weekly during NACT or to a waitlist control group(WCG,n=60).The primary outcome,“change in tumor size”,as well as the secondary clinical outcomes pathologic complete response(pCR),type of surgery(breast conserving/mastectomy),axillary lymph node dissection(ALND,yeso),premature discontinuation of chemotherapy(yeso),and relative dose intensity(RDI)were derived from clinical records.Due to the highly skewed distribution,the primary outcome was categorized.Multiple(ordinal)logistic regression analyses were performed.Results Overall,there was no significant difference in post-intervention tumor size between RT or AT and WCG.However,there was a significant effect modification by hormone receptor(HR)status(Pinteraction=0.030).Among patients with HR+tumors,results suggest a beneficial effect of AT on tumor shrinkage(odds ratio(OR)=2.37,95%confidence interval(95%CI):0.97‒5.78),on pCR(OR=3.21,95%CI:0.97‒10.61);and on ALND(OR=3.76,95%CI:0.78‒18.06)compared to WCG.The effects of RT were slightly less pronounced.For HR−subtypes,beneficial effects on RDI were found for AT(OR=3.71,95%CI:1.20‒11.50)and similarly for RT(OR=2.58,95%CI:0.88‒7.59).Both AT and RT had favorable effects on premature discontinuation of chemotherapy(OR(no vs.yes)=2.34,95%CI:1.10‒5.06),irrespective of tumor receptor status.Conclusion While there was no significant effect on the primary outcome in the overall group,aerobic and resistance exercise concomitant to NACT seem to beneficially affect tumor shrinkage and pCR,reduce the need for ALND among patients with HR+breast cancers,and prevent low RDI among patients with HR–breast cancers.These results warrant confirmation in further trials. 展开更多
关键词 Supervised exercise Neoadjuvant chemotherapy Tumor response Pathologic complete response Clinical cancer outcomes
暂未订购 下载PDF
Proximal gastrectomy with tubular stomach reconstruction vs total gastrectomy for proximal gastric cancer following neoadjuvant chemotherapy:A multicenter retrospective study 认领 引用 被引量：1
7
作者 Yi-Ming Lu Peng Jin +5 位作者 Hai-Kuo Wang Xin-Xin Shao Hai-Tao Hu Yu-Juan Jiang Wang-Yao Li Yan-Tao Tian 《World Journal of Gastrointestinal Surgery》 SCIE 2025年第5期103-116,共14页
BACKGROUND Gastric cancer(GC)is a major global health challenge,and the treatment of proximal GC in particular presents unique clinical and surgical complexities.Currently,there is no consensus on whether proximal gas... BACKGROUND Gastric cancer(GC)is a major global health challenge,and the treatment of proximal GC in particular presents unique clinical and surgical complexities.Currently,there is no consensus on whether proximal gastrectomy(PG)or total gastrectomy(TG)should be used for advanced proximal GC,and the choice of postoperative gastrointestinal reconstruction method remains controversial.AIM To compare the short-term efficacy,long-term survival,and postoperative reflux outcomes of PG with tubular stomach reconstruction vs TG with Roux-en-Y re-construction in patients with proximal GC following neoadjuvant chemotherapy(NACT)in an effort to provide valuable insights for clinical decision-making regarding the optimal surgical approach.METHODS A multicenter retrospective cohort study was conducted at two Chinese medical centers between December,2012 and December,2022.Patients with histologically confirmed proximal GC who received NACT followed by either PG with tubular stomach reconstruction or TG with Roux-en-Y reconstruction were included.Propensity score matching(PSM)was performed to balance baseline characteristics,and the primary endpoint was 5-year overall survival(OS).Se-condary endpoints included recurrence-free survival(RFS),postoperative complications,and reflux severity.RESULTS After PSM,244 patients(122 PG,122 TG)were finally included and all baseline characteristics were comparable between groups.The PG group had a significantly shorter operation time compared to the TG group(189.50 vs 215.00 minutes,P<0.001),with no differences in intraoperative blood loss or postoperative complications(19.68%vs 14.75%,P=0.792).The 5-year OS rates were 52.7%vs 45.5%(P=0.330),and 5-year RFS rates were 54.3%vs 47.6%(P=0.356)for the PG and TG groups,respectively.Reflux symptoms(18.0%vs 31.1%,P=0.017)and clinically significant reflux based on gastroesophageal reflux disease questionnaire scores≥8(7.4%vs 21.3%,P<0.001)were significantly less frequent in the PG group.Multivariate analysis identified histological differentiation(HR=2.98,95%CI:2.03-4.36,P<0.001)and tumor size(HR=0.26,95%CI:0.17-0.41 for tumors≤4 cm,P<0.001)as independent prognostic factors.CONCLUSION PG with tubular stomach reconstruction is comparable to TG in terms of surgical safety and long-term oncological outcomes for proximal GC patients following NACT.Additionally,PG has the advantages of shorter operation time and lower rates of postoperative reflux,suggesting potential benefits for patient quality of life.Notably,the analysis of postoperative prognostic factors,including histological differentiation and tumor size,further informs clinical decision-making and highlights the importance of individualized treatment strategies. 展开更多
关键词 Proximal gastric cancer Proximal gastrectomy Total gastrectomy Neoadjuvant chemotherapy Tubular stomach reconstruction Reflux
暂未订购 下载PDF
Baohe Pingwei power plus neoadjuvant chemotherapy for gastric cancer 认领 引用
8
作者 Hong-Yu Ma Xin Liu +4 位作者 Yuan-Wu Chen Jing Liang Jie Wang Ming-Ming Zhang Qian Yang 《World Journal of Gastrointestinal Surgery》 SCIE 2025年第7期255-265,共11页
BACKGROUND Neoadjuvant chemotherapy improves the resection rate and reduces postoperative recurrence in gastric cancer(GC)but is often associated with significant toxicity.Traditional Chinese medicine has unique advan... BACKGROUND Neoadjuvant chemotherapy improves the resection rate and reduces postoperative recurrence in gastric cancer(GC)but is often associated with significant toxicity.Traditional Chinese medicine has unique advantages in the treatment of cancer,and Baohe Pingwei powder can help alleviate the side effects of chemotherapy and enhance the therapeutic effect.However,there is no clinical evidence supporting its use in patients who underwent surgery for GC treatment.AIM To evaluate the safety and efficacy of Baohe Pingwei powder combined with neoadjuvant chemotherapy in postoperative patients with GC and to provide evidence-based medical evidence for the treatment of postoperative patients with GC with integrated traditional Chinese and Western medicine.METHODS A retrospective analysis was conducted on 80 postoperative patients with GC admitted to the Department of Gastroenterology of our hospital and treated between May 2024 and November 2024.According to different treatment methods,they were divided into a control group(54 patients received S-1+oxaliplatin chemotherapy 4 weeks after surgery)and a study group(26 cases were combined with Baohe Pingwei powder combined with S-1+oxaliplatin).Clinical data were collected to compare the differences in objective response rate(ORR),disease control rate(DCR),progression-free survival,overall survival,and adverse reactions of patients with GC after surgery under different treatment methods.Further based on the control of GC,patients were divided into an effective group(62 cases)and an ineffective group(18 cases).The relationship between Baohe Pingwei powder and clinical efficacy was analyzed through univariate and multivariate logistic regression analysis as well as a multivariate Cox risk model.RESULTS The baseline characteristics including age,gender,and other demographic factors showed no significant differences between the control and observation groups(P>0.05).In the observation group,there were 24 cases of effective treatment and 2 cases of ineffective treatment,with an ORR of 84.62%and a DCR of 92.31%.In the control group,there were 38 cases of effective treatment and 16 cases of ineffective treatment,with an ORR of 46.30%and a DCR of 70.37%.The treatment effect of the observation group was significantly higher than that of the control group(P<0.05).The Kaplan Meier curve showed that the risk of tumor recurrence and death in the observation group was significantly reduced compared to the control group(log rank P=0.030 and P=0.035,respectively).Subsequent stratification based on treatment response identified 62 patients in the effective group and 18 in the ineffective group.Intergroup comparison showed that the effective group had a higher proportion of Baohe Pingwei powder(P=0.000),and there were statistically significant differences in tumor size,differentiation degree,and post-treatment levels of CD3+,CD4+,CA19-9,CA242,IL-6,IL-10,and TNF-αbetween the groups(P<0.05).Further univariate and multivariate logistic analysis revealed that CD3+and CD4+T cell levels were significantly associated with treatment efficacy.The use of Baohe Pingwei powder was a protective factor for effective treatment,while CA19-9 and IL-6 levels were independent risk factors for ineffective treatment(P<0.05).Multivariate Cox proportional hazards model analysis found that without adjusting the model,the risk of ineffective treatment in patients significantly decreased with the increase of CD3+and CD4+and the decrease of CA19-9 and IL-6(group 1 as a reference;group 2 hazard ratio:0.624,95%confidence interval:0.437-0.986,P=0.019).After adjusting for confounding factors such as Baohe Pingwei powder in Model 3,Cox regression results showed an increased risk of treatment failure.With the decrease of CD3+and CD4+and the increase of CA19-9 and IL-6,the risk of treatment failure in patients significantly increased(Group 1 as a reference;Group 2 hazard ratio:1.439,95%confidence interval:1.208-1.614,P=0.006).CONCLUSION The combination therapy of Baohe Pingwei powder with neoadjuvant chemotherapy demonstrated significant clinical benefits in postoperative patients with GC,including improved the ORR,DCR,extended progression-free survival,and overall survival as well as a reduced incidence of treatment-related adverse events.Furthermore,our finding indicated that decreased CD3+and CD4+levels along with evaluated CA199 and IL-6 levels served as important biomarkers predicting increased risk of treatment failure in this patient population. 展开更多
关键词 Baohe Pingwei powder Neoadjuvant chemotherapy Gastric cancer Security Effectiveness
暂未订购 下载PDF
Impact of hormone receptor and HER2 conversions on survival after neoadjuvant chemotherapy in breast cancer patients 认领 引用
9
作者 Ran Feng Lihui Pan +2 位作者 Yarong Yao Jinnan Gao Xiaojun Zhang 《Oncology and Translational Medicine》 CAS CSCD 2025年第2期73-80,共8页
Background:This study assessed the frequency of changes in some key receptor status of tumors after neoadjuvant chemotherapy(NAC)in patients with invasive breast cancer and the prognostic impact of these changes.Metho... Background:This study assessed the frequency of changes in some key receptor status of tumors after neoadjuvant chemotherapy(NAC)in patients with invasive breast cancer and the prognostic impact of these changes.Methods:This study included 300 patients diagnosed with invasive breast cancer who were treated with both NAC and surgery between 2012 and 2021.The hormone receptor(HR)and human epidermal growth factor receptor 2(HER2)levels were measured before and after NAC.The prognostic impact of receptor conversion was also evaluated in patients receiving NAC,by using the Kaplan-Meier method and Cox proportional hazards models as statistical methods.Results:The conversion rate of estrogen receptor–positive(ER+)to ER-negative(ER-)was similar to that of ER-to ER+(9.2%and10.9%,respectively).The proportion of HR-to HR+was remarkably higher than that of HR+to HR-(14.8%vs 9.2%,respectively).The change from HER2+to HER2-was significantly more frequently than that from HER2-to HER2+(20.3%vs 6%,respectively).Patients with ER and HR status changes from(-)to(+)after NAC had significantly worse recurrence-free survival(RFS)and overall survival(OS)than those in the other 3 groups(ER-to ER+:RFS:p=0.002,OS:p<0.001;HR-to HR+:RFS:p=0.003,OS:p<0.001).The 4 HER2 conversion subgroups were not significantly associated with RFS or OS.Conclusions:This study demonstrated a discordance in HR status after NAC and identified predictors of conversion.Patients whose HR status switched to positive after NAC had the worst 3-year RFS and OS rates. 展开更多
关键词 Neoadjuvant chemotherapy Breast cancer Receptor conversions Discordance Prognostic impact
暂未订购 下载PDF
Neutrophil extracellular traps predict sensitivity to neoadjuvant chemotherapy combined with immunotherapy in locally advanced gastric cancer 认领 引用
10
作者 Yuan Lv Wei-Xuan Li +7 位作者 Liang Sun Lin-Pu Xin Tao Li Wen-Tao Zhong Hong-Yan Zhu Ran An Ai-Jun Liu Lin Chen 《World Journal of Gastrointestinal Oncology》 SCIE 2025年第7期209-219,共11页
BACKGROUND Neutrophil extracellular traps(NETs)are associated with an immunosuppressive tumor microenvironment and may influence the efficacy of immune-based therapies.However,their role in neoadjuvant chemotherapy co... BACKGROUND Neutrophil extracellular traps(NETs)are associated with an immunosuppressive tumor microenvironment and may influence the efficacy of immune-based therapies.However,their role in neoadjuvant chemotherapy combined with immunotherapy(NACI)for locally advanced gastric cancer(LAGC)remains unclear.AIM To investigate the prognostic and predictive value of NET density in LAGC patients undergoing NACI.METHODS We enrolled 31 LAGC patients treated with NACI.NET density was assessed through dual immunofluorescence staining of citrullinated histone H3 and myeloperoxidase in pretreatment biopsy and post-treatment surgical specimens.Patients were stratified into high and low pre-NACI NET groups based on median NET density.Pathological complete response(pCR)and overall response rates were evaluated in relation to NET density.Logistic regression analyses were performed to identify independent predictors of treatment outcomes.Dynamic changes in NET density during NACI were also analyzed.RESULTS Patients with low pre-NACI NET density demonstrated significantly higher rates of pCR(40%vs 6%,P=0.037)and overall response(53%vs 12%,P=0.023)compared to those with high NET density.Low pre-NACI NET density and higher programmed death protein ligand 1 expression were identified as independent protective factors for achieving pCR and better response rates.NACI increased NET density;however,this increase was primarily observed in non-pCR and nonresponder groups.Patients in the pCR and responder groups showed stable NET density before and after treatment.Higher post-NACI NET density was associated with poorer respond to NACI.High post-NACI NET density was associated with increased infiltration of immunosuppressive FOXP3+T regulatory cells(P=0.025)and CD68+macrophages(P=0.038).CONCLUSION Pre-NACI NET density serves as a prognostic and predictive biomarker for NACI efficacy in LAGC patients.Low pretreatment NET density is associated with favorable outcomes,while increased post-treatment NET density correlates with poorer response.Targeting NET formation may represent a novel therapeutic strategy to enhance NACI efficacy in LAGC. 展开更多
关键词 Neutrophil extracellular traps Locally advanced gastric cancer Neoadjuvant chemotherapy Neoadjuvant immunotherapy Treatment sensitivity
暂未订购 下载PDF
Significance of hemoglobin and hematocrit changes in predicting patient survival and efficacy of neoadjuvant chemotherapy for advanced gastric cancer 认领 引用
11
作者 Ti-Hong Qiu Hong-You Wen Yi-Long Huang 《World Journal of Gastrointestinal Oncology》 SCIE 2025年第6期195-203,共9页
BACKGROUND Advanced gastric cancer is characterized by fast tumor growth and aggressive biological behavior.During neoadjuvant chemotherapy,patients are at risk of distant metastasis or local progression.Anemia is a f... BACKGROUND Advanced gastric cancer is characterized by fast tumor growth and aggressive biological behavior.During neoadjuvant chemotherapy,patients are at risk of distant metastasis or local progression.Anemia is a frequent complication in these patients.AIM To analyze whether changes in hemoglobin and hematocrit can predict the survival and efficacy of neoadjuvant chemotherapy in patients with advanced gastric cancer.METHODS The clinical data of 185 patients with advanced gastric cancer admitted to the Third Affiliated Hospital of Chengdu Medical College,Pidu District People’s Hospital,Chengdu,China,between January 2016 and January 2021,were retrospectively analyzed.All patients underwent a tegafur+oxaliplatin+apatinib chemotherapy regimen.According to the efficacy of chemotherapy,they were divided into an effective group(complete or partial response,n=121)and an ineffective group(stable disease or disease progression,n=64).The factors related to chemotherapy efficacy in patients with advanced gastric cancer were analyzed by univariate and logistic multivariate analyses.The 3-year survival rates of the patients with different hemoglobin and hematocrit levels were compared.RESULTS Univariate analysis showed that the proportion of patients with a tumor diameter>5 cm,non-tubular adenocarcinoma,lymph node metastasis,hematocrit266×109/L in the ineffective group were significantly higher than those in the effective group(P5 cm,lymph node metastasis,≤3 chemotherapy cycles,hematocrit<33%,and hemoglobin<107 g/L are risk factors for neoadjuvant chemotherapy failure in advanced gastric cancer(P<0.05).The 1-year,2-year,and 3-year survival rates in the effective group were 93.39%,83.47%,and 60.33%,respectively.These rates were significantly higher than those in the ineffective group(P<0.05).The 1-year,2-year,and 3-year survival rates of patients with hematocrit<33%were 74.67%,49.33%,and 29.33%,respectively,which were significantly lower than those of patients with hematocrit≥33%(P<0.05).The 1-year,2-year,and 3-year survival rates of patients with hemoglobin<107 g/L were 80.39%,58.82%,and 39.22%,respectively,which were significantly lower than those of patients with hemoglobin≥107 g/L(P<0.05).CONCLUSION Hematocrit<33%and hemoglobin<107 g/L are risk factors for chemotherapy failure in patients with advanced gastric cancer.They are associated with poorer prognosis and reduced 3-year survival rates. 展开更多
关键词 Chemotherapy curative effect Gastric cancer Hematocrit Hemoglobin Neoadjuvant chemotherapy Progress Survival
暂未订购 下载PDF
Computed tomography 3D reconstruction and texture analysis for evaluating the efficacy of neoadjuvant chemotherapy in advanced gastric cancer 认领 引用
12
作者 Chun-Ye Wang Lei Zhang Jing-Wei Ma 《World Journal of Gastrointestinal Surgery》 SCIE 2025年第6期146-158,共13页
BACKGROUND Gastric cancer(GC)remains a significant global health challenge,with high incidence and mortality rates.Neoadjuvant chemotherapy is increasingly used to improve surgical outcomes and long-term survival in a... BACKGROUND Gastric cancer(GC)remains a significant global health challenge,with high incidence and mortality rates.Neoadjuvant chemotherapy is increasingly used to improve surgical outcomes and long-term survival in advanced cases.However,individual responses to treatment vary widely,and current imaging methods often fall short in accurately predicting efficacy.Advanced imaging techniques,such as computed tomography(CT)3D reconstruction and texture analysis,offer potential for more precise assessment of therapeutic response.AIM To explore the application value of CT 3D reconstruction volume change rate,texture feature analysis,and visual features in assessing the efficacy of neoadjuvant chemotherapy for advanced GC.METHODS A retrospective analysis was conducted on the clinical and imaging data of 97 patients with advanced GC who received S-1 plus Oxaliplatin combined chemotherapy regimen neoadjuvant chemotherapy from January 2022 to March 2024.CT texture feature analysis was performed using MaZda software,and ITK-snap software was used to measure the tumor volume change rate before and after chemotherapy.CT visual features were also evaluated.Using postoperative pathological tumor regression grade(TRG)as the gold standard,the correlation between various indicators and chemotherapy efficacy was analyzed,and a predictive model was constructed and internally validated.RESULTS The minimum misclassification rate of texture features in venous phase CT images(7.85%)was lower than in the arterial phase(13.92%).The volume change rate in the effective chemotherapy group(75.20%)was significantly higher than in the ineffective group(41.75%).There was a strong correlation between volume change rate and TRG grade(r=-0.886,P<0.001).Multivariate analysis showed that gastric wall peristalsis(OR=0.286)and thickness change rate≥40%(OR=0.265)were independent predictive factors.Receiver operating characteristic curve analysis indicated that the volume change rate[area under the curve(AUC)=0.885]was superior to the CT visual feature model(AUC=0.795).When the cutoff value was 82.56%,the sensitivity and specificity were 85.62%and 96.45%,respectively.CONCLUSION The CT 3D reconstruction volume change rate can serve as a preferred quantitative indicator for evaluating the efficacy of neoadjuvant chemotherapy in GC.Combining it with a CT visual feature predictive model can further improve the accuracy of efficacy evaluation. 展开更多
关键词 Gastric cancer Neoadjuvant chemotherapy Computed tomography 3D reconstruction Efficacy evaluation
暂未订购 下载PDF
Retrospective analysis of predictive factors for pathological complete response after neoadjuvant chemotherapy in gastric cancer 认领 引用
13
作者 Bo Bi Chen Liu +1 位作者 Jie Chai Yun-Ming Duan 《World Journal of Gastrointestinal Surgery》 SCIE 2025年第10期235-245,共11页
BACKGROUND Gastric cancer is a malignant tumor with high morbidity and mortality worldwide.Neoadjuvant chemotherapy(NAC),defined as chemotherapy administered before the primary treatment(usually surgery)to reduce tumo... BACKGROUND Gastric cancer is a malignant tumor with high morbidity and mortality worldwide.Neoadjuvant chemotherapy(NAC),defined as chemotherapy administered before the primary treatment(usually surgery)to reduce tumor size and control micrometastases,has emerged as a crucial therapeutic strategy for locally advanced gastric cancer.Pathological complete response(pCR),characterized by the absence of viable tumor cells in the resected specimen after neoadjuvant treatment,is recognized as a strong predictor of favorable prognosis.However,the factors influencing the achievement of pCR remain incompletely understood.AIM To identify and analyze the predictive factors associated with achieving pCR after NAC in gastric cancer patients,thereby providing evidence-based guidance for clinical decision-making.METHODS A retrospective analysis was performed on 215 patients from Shandong Cancer Hospital and Tai’an Central Hospital with locally advanced gastric cancer who underwent NAC followed by radical surgery at our hospital between January 2015 and December 2023.Comprehensive clinical and pathological data were collected,including age,gender,tumor location,Lauren classification,clinical staging,chemotherapy regimens,number of chemotherapy cycles,and baseline hematological indicators.The baseline hematological indicators included neutrophil-to-lymphocyte ratio(NLR),platelet-to-lymphocyte ratio,albumin level,carcinoembryonic antigen(CEA),and carbohydrate antigen 19-9.Univariate and multivariate logistic regression analyses were employed to determine the independent predictive factors for pCR.RESULTS Among 215 gastric cancer patients,41(19.1%)achieved pCR after NAC.Multivariate analysis identified five independent predictive factors for pCR:Lauren intestinal type[odds ratio(OR)=3.28],lower clinical T stage(OR=2.75),CEA decrease≥70%after NAC(OR=3.42),pre-treatment NLR<2.5(OR=2.13),and≥4 chemotherapy cycles(OR=2.87).The fluorouracil,leucovorin,oxaliplatin,docetaxel regimen achieved the highest pCR rate(27.5%),and oxaliplatin-containing regimens were superior to cisplatin-containing regimens(22.3%vs 12.7%,P=0.034).Patients with both low NLR and platelet-to-lymphocyte ratio had the highest pCR rate(33.8%),while those with both high inflammatory markers had the lowest rate(10.7%).Earlier clinical stage disease(cT3N+vs cT4N+:28.6%vs 13.0%)and lower lymph node burden were associated with higher pCR rates.CONCLUSION The achievement of pCR after NAC in gastric cancer patients is closely associated with Lauren intestinal type,lower clinical T stage,a significant decrease in CEA after chemotherapy,low pre-treatment NLR,and an adequate number of chemotherapy cycles. 展开更多
关键词 Gastric cancer Neoadjuvant chemotherapy Pathological complete response Predictive factor
暂未订购 下载PDF
Surgical outcome after docetaxel-based neoadjuvant chemotherapy in locally-advanced gastric cancer 认领 引用 被引量：52
14
作者 Roberto Biffi Nicola Fazio +10 位作者 Fabrizio Luca Antonio Chiappa Bruno Andreoni Maria Giulia Zampino Arnaud Roth Jan Christian Schuller Giancarla Fiori Franco Orsi Guido Bonomo Cristiano Crosta Olivier Huber 《World Journal of Gastroenterology》 SCIE CAS 2010年第7期868-874,共7页
AIM:To investigate feasibility,morbidity and surgical mortality of a docetaxel-based chemotherapy regimen randomly administered before or after gastrectomy in patients suffering from locally-advanced resectable gastri... AIM:To investigate feasibility,morbidity and surgical mortality of a docetaxel-based chemotherapy regimen randomly administered before or after gastrectomy in patients suffering from locally-advanced resectable gastric cancer.METHODS:Patients suffering from locally-advanced(T3-4 any N M0 or any T N1-3 M0)gastric carcinoma,staged with endoscopic ultrasound,bone scan,computed tomography,and laparoscopy,were assigned to receive four 21 d/cycles of TCF(docetaxel 75 mg/m 2 day 1,cisplatin 75 mg/m 2 day 1,and fluorouracil 300 mg/m 2 per day for days 1-14),either before(Arm A)or after(Arm B)gastrectomy.Operative morbidity,overall mortality,and severe adverse events were compared by intention-to-treat analysis.RESULTS:From November 1999 to November 2005,70 patients were treated.After preoperative TCF(Arm A),thirty-two(94%)resections were performed,85% of which were R0.Pathological response was complete in 4 patients(11.7%),and partial in 18(55%).No surgical mortality and 28.5%morbidity rate were observed,similar to those of immediate surgery arm(P= 0.86).Serious chemotherapy adverse events tended to be more frequent in arm B(23%vs 11%,P=0.07),with a single death per arm.CONCLUSION:Surgery following docetaxel-based chemotherapy was safe and with similar morbidity to immediate surgery in patients with locally-advanced resectable gastric carcinoma. 展开更多
关键词 Gastric cancer Docetaxel Neoadjuvant chemotherapy Laparoscopy Endoscopic ultrasonography Morbidity
暂未订购 下载PDF
Computed tomography-based radiomics for prediction of neoadjuvant chemotherapy outcomes in locally advanced gastric cancer: A pilot study 认领 引用 被引量：26
15
作者 Zhenhui Li Dafu Zhang +6 位作者 Youguo Dai Jian Dong Lin Wu Yajun Li Zixuan Cheng Yingying Ding Zaiyi Liu 《Chinese Journal of Cancer Research》 SCIE CAS CSCD 2018年第4期406-414,共9页
Objective： The standard treatment for patients with locally advanced gastric cancer has relied on perioperativeradio-chemotherapy or chemotherapy and surgery. The aim of this study was to investigate the wealth of ra... Objective： The standard treatment for patients with locally advanced gastric cancer has relied on perioperativeradio-chemotherapy or chemotherapy and surgery. The aim of this study was to investigate the wealth of radiomicsfor pre-treatment computed tomography （CT） in the prediction of the pathological response of locally advancedgastric cancer with preoperative chemotherapy.Methods： Thirty consecutive patients with CT-staged Ⅱ/Ⅲ gastric cancer receiving neoadjuvant chemotherapywere enrolled in this study between December 2014 and March 2017. All patients underwent upper abdominal CTduring the unenhanced, late arterial phase （AP） and portal venous phase （PP） before the administration ofneoadjuvant chemotherapy. In total, 19,985 radiomics features were extracted in the AP and PP for each patient.Four methods were adopted during feature selection and eight methods were used in the process of building theclassifier model. Thirty-two combinations of feature selection and classification methods were examined. Receiveroperating characteristic （ROC） curves were used to evaluate the capability of each combination of feature selectionand classification method to predict a non-good response （non-GR） based on tumor regression grade （TRG）.Results： The mean area under the curve （AUC） ranged from 0.194 to 0.621 in the AP, and from 0.455 to 0.722in the PP, according to different combinations of feature selection and the classification methods. There was onlyone cross-combination machine-learning method indicating a relatively higher AUC （〉0.600） in the AP, while 12cross-combination machine-learning methods presented relatively higher AUCs （all 〉0.600） in the PP. The featureselection method adopted by a filter based on linear discriminant analysis ＋ classifier of random forest achieved asignificantly prognostic performance in the PP （AUC, 0.722~0.108; accuracy, 0.793; sensitivity, 0.636; specificity,0.889; Z=2.039; P=0.041）.Conclusions： It is possible to predict non-GR after neoadiuvant chemotherapy in locally advanced gastriccancers based on the radiomics of CT. 展开更多
关键词 Gastric cancer neoadjuvant chemotherapy radiomics tomography spiral computed
暂未订购 下载PDF
CapOX as neoadjuvant chemotherapy for locally advanced operable colon cancer patients: a prospective single-arm phase Ⅱ trial 认领 引用 被引量：21
16
作者 Fangqi Liu Li Yang +11 位作者 Yuchen Wu Cong Li Jiang Zhao Adili Keranmu Hongtu Zheng Dan Huang Lei Wang Tong Tong Junyan Xu Ji Zhu Sanjun Cai Ye Xu 《Chinese Journal of Cancer Research》 SCIE CAS CSCD 2016年第6期589-597,共9页
Objective： The aim of this prospective, single-arm phase II trial was to confirm the safety and efficacy of neoadjuvant chemotherapy（NAC） using oxaliplatin plus capecitabine（Cap OX） for patients with operable loc... Objective： The aim of this prospective, single-arm phase II trial was to confirm the safety and efficacy of neoadjuvant chemotherapy（NAC） using oxaliplatin plus capecitabine（Cap OX） for patients with operable locally advanced colon cancer（CC）.Methods： Patients with computed tomography-defined T4 or lymph node-positive CCs were enrolled. After radiological staging, patients were treated with at least 2 cycles of NAC consisting of 130 mg/m2 oxaliplatin on d 1,plus 1,000 mg/m2 capecitabine twice daily for 14 d every 3 weeks, followed by surgery, and then with the rest cycles of adjuvant chemotherapy. Radiological response was evaluated after 2 cycles of NAC. Tumor response, treatment toxicity, and surgical complications were recorded. The pathological response to therapy was evaluated according to the tumor regression grade（TRG） score. The primary endpoint was pathologic tumor response. This trial is registered in Clinical Trials.gov（No： NCT02415829）.Results： Forty-seven patients were enrolled in the study. Forty-two patients completed the planned treatments.The total radiological response rate was 68%（32/47）, including complete and partial response rates of 2%（1/47）and 66%（31/47）, respectively. Stable disease was observed in 32%（15/47） and progressive disease was observed in none. Complete pathologic response, major regression, and at least moderate regression were achieved in 1（2%）, 2（4%）, and 29（62%） patients, respectively. Four patients developed grade 3 treatment toxicities. One patient with wound infection occurred after operation（1/47, 2%）. There was no treatment-related death.Conclusions： Our results suggest that NAC with Cap OX is an effective and safe treatment option for patients with locally advanced CCs. 展开更多
关键词 Colon cancer neoadjuvant chemotherapy phase II trial surgery
暂未订购 下载PDF
Neoadjuvant chemotherapy for advanced gastric cancer:A meta-analysis 认领 引用 被引量：29
17
作者 Wei Li Tian-Shu Liu +1 位作者 Jing Qin Yi-Hong Sun 《World Journal of Gastroenterology》 SCIE CAS 2010年第44期5621-5628,共8页
AIM:To study the value of neoadjuvant chemotherapy (NAC) for advanced gastric cancer by performing a meta-analysis of the published studies.METHODS:All published controlled trials of NAC for advanced gastric cancer vs... AIM:To study the value of neoadjuvant chemotherapy (NAC) for advanced gastric cancer by performing a meta-analysis of the published studies.METHODS:All published controlled trials of NAC for advanced gastric cancer vs no therapy before surgery were searched.Studies that included patients with metastases at enrollment were excluded.Databases included Cochrane Library of Clinical Comparative Trials,MEDLINE,Embase,and American Society of Clinical Oncology meeting abstracts from 1978 to 2010.The censor date was up to April 2010.Primary outcome was the odds ratio (OR) for improving overall survival rate of patients with advanced gastric cancer.Secondary outcome was the OR for down-staging tumor and increasing R0 resection in patients with advanced gastric cancer.Safety analyses were also performed.All calculations and statistical tests were performed using RevMan 5.0 software.tric cancer enrolled in 14 trials were divided into NAC group (n=1054) and control group (n=1217).The patients were followed up for a median time of 54 mo.NAC significantly improved the survival rate [OR=1.27,95% confidence interval (CI):1.04-1.55],tumor stage (OR=1.71,95% CI:1.26-2.33) and R0 resection rate (OR=1.51,95% CI:1.19-1.91) of patients with advanced gastric cancer.No obvious safety concerns were raised in these trials.CONCLUSION:NAC can improve tumor stage and survival rate of patients with advanced gastric cancer with a rather good safety. 展开更多
关键词 Gastric cancer Neoadjuvant chemotherapy Survival Meta-analysis
暂未订购 下载PDF
Multi-modal radiomics model to predict treatment response to neoadjuvant chemotherapy for locally advanced rectal cancer 认领 引用 被引量：17
18
作者 Zheng-Yan Li Xiao-Dong Wang +8 位作者 Mou Li Xi-Jiao Liu Zheng Ye Bin Song Fang Yuan Yuan Yuan Chun-Chao Xia Xin Zhang Qian Li 《World Journal of Gastroenterology》 SCIE CAS 2020年第19期2388-2402,共15页
BACKGROUND Neoadjuvant chemotherapy is currently recommended as preoperative treatment for locally advanced rectal cancer(LARC);however,evaluation of treatment response to neoadjuvant chemotherapy is still challenging... BACKGROUND Neoadjuvant chemotherapy is currently recommended as preoperative treatment for locally advanced rectal cancer(LARC);however,evaluation of treatment response to neoadjuvant chemotherapy is still challenging.AIM To create a multi-modal radiomics model to assess therapeutic response after neoadjuvant chemotherapy for LARC.METHODS This retrospective study consecutively included 118 patients with LARC who underwent both computed tomography(CT)and magnetic resonance imaging(MRI)before neoadjuvant chemotherapy between October 2016 and June 2019.Histopathological findings were used as the reference standard for pathological response.Patients were randomly divided into a training set(n=70)and a validation set(n=48).The performance of different models based on CT and MRI,including apparent diffusion coefficient(ADC),dynamic contrast enhanced T1 images(DCE-T1),high resolution T2-weighted imaging(HR-T2WI),and imaging features,was assessed by using the receiver operating characteristic curve analysis.This was demonstrated as area under the curve(AUC)and accuracy(ACC).Calibration plots with Hosmer-Lemeshow tests were used to investigate the agreement and performance characteristics of the nomogram.RESULTS Eighty out of 118 patients(68%)achieved a pathological response.For an individual radiomics model,HR-T2WI performed better(AUC=0.859,ACC=0.896)than CT(AUC=0.766,ACC=0.792),DCE-T1(AUC=0.812,ACC=0.854),and ADC(AUC=0.828,ACC=0.833)in the validation set.The imaging performance for extramural venous invasion detection was relatively low in both the training(AUC=0.73,ACC=0.714)and validation(AUC=0.578,ACC=0.583)sets.The multi-modal radiomics model reached an AUC of 0.925 and ACC of 0.886 in the training set,and an AUC of 0.93 and ACC of 0.875 in the validation set.For the clinical radiomics nomogram,good agreement was found between the nomogram prediction and actual observation.CONCLUSION A multi-modal nomogram using traditional imaging features and radiomics of preoperative CT and MRI adds accuracy to the prediction of treatment outcome,and thus contributes to the personalized selection of neoadjuvant chemotherapy for LARC. 展开更多
关键词 Radiomics Rectal cancer Neoadjuvant chemotherapy Magnetic resonance imaging Computed tomography
暂未订购 下载PDF
Nomogram for predicting pathological complete response to neoadjuvant chemotherapy in patients with advanced gastric cancer 认领 引用 被引量：12
19
作者 Yong-He Chen Jian Xiao +4 位作者 Xi-Jie Chen Hua-She Wang Dan Liu Jun Xiang Jun-Sheng Peng 《World Journal of Gastroenterology》 SCIE CAS 2020年第19期2427-2439,共13页
BACKGROUND Survival benefit of neoadjuvant chemotherapy(NAC)for advanced gastric cancer(AGC)is a debatable issue.Studies have shown that the survival benefit of NAC is dependent on the pathological response to chemoth... BACKGROUND Survival benefit of neoadjuvant chemotherapy(NAC)for advanced gastric cancer(AGC)is a debatable issue.Studies have shown that the survival benefit of NAC is dependent on the pathological response to chemotherapy drugs.For those who achieve pathological complete response(pCR),NAC significantly prolonged prolapsed-free survival and overall survival.For those with poor response,NAC yielded no survival benefit,only toxicity and increased risk for tumor progression during chemotherapy,which may hinder surgical resection.Thus,predicting pCR to NAC is of great clinical significance and can help achieve individualized treatment in AGC patients.AIM To establish a nomogram for predicting pCR to NAC for AGC patients.METHODS Two-hundred and eight patients diagnosed with AGC who received NAC followed by resection surgery from March 2012 to July 2019 were enrolled in this study.Their clinical data were retrospectively analyzed by logistic regression analysis to determine the possible predictors for pCR.Based on these predictors,a nomogram model was developed and internally validated using the bootstrap method.RESULTS pCR was confirmed in 27 patients(27/208,13.0%).Multivariate logistic regression analysis showed that higher carcinoembryonic antigen level,lymphocyte ratio,lower monocyte count and tumor differentiation grade were associated with higher pCR.Concordance statistic of the established nomogram was 0.767.CONCLUSION A nomogram predicting pCR to NAC was established.Since this nomogram exhibited satisfactory predictive power despite utilizing easily available pretreatment parameters,it can be inferred that this nomogram is practical for the development of personalized treatment strategy for AGC patients. 展开更多
关键词 Advanced gastric cancer Neoadjuvant chemotherapy Nomogram Pathological complete response
暂未订购 下载PDF
Neoadjuvant chemotherapy for locally advanced cervical cancer 认领 引用 被引量：21
20
作者 Takashi Iwata Azumi Miyauchi +9 位作者 Yukako Suga Hiroshi Nishio Masaru Nakamura Akiko Ohno Nobumaru Hirao Tohru Morisada Kyoko Tanaka Hiroki Ueyama Hidemichi Watari Daisuke Aoki 《Chinese Journal of Cancer Research》 SCIE CAS CSCD 2016年第2期235-240,共6页
Neoadjuvant chemotherapy followed by surgery （NCS） has not been fully evaluated clinically. Currently, the main regimen of neoadjuvant chemotherapy （NAC） used in NCS includes cisplatin. The antitumor effects of NA... Neoadjuvant chemotherapy followed by surgery （NCS） has not been fully evaluated clinically. Currently, the main regimen of neoadjuvant chemotherapy （NAC） used in NCS includes cisplatin. The antitumor effects of NAC reduce lymph node metastasis and the tumor diameter in patients prior to surgery, and this can reduce the number of high risk patients who require postoperative radiation therapy. Many randomized controlled trials （RCTs） have examined the long-term prognosis of NCS compared to primary surgery, but the utility of NCS remains uncertain. The advent of concurrent chemoradiotherapy （CCRT） has markedly improved the outcome of radiotherapy （RT）, and CCRT is now used as a standard method in many cases of advanced bulky cervical cancer. NCS gives a better treatment outcome than radiation therapy alone, but it is important to verify that NCS gives a similar or better outcome compared to CCRT. 展开更多
关键词 Neoadjuvant chemotherapy （NAC） cervical cancer
暂未订购 下载PDF
已选0条
引用分析
参考文献
引证文献
 统计分析
检索结果
已选文献
上一页 1 2 … 10 下一页 到第 页
在线咨询 使用帮助 返回顶部 意见反馈